Biotech major Biocon on Tuesday settled nearly 13 per cent up on the Bombay Stock Exchange,after touching all-time high during the day,on reports of its USD 350 million (Rs 1,550 crore) global marketing deal with the US-based drug firm Pfizer.
Reacting positively to the pact,Biocon zoomed 12.97 per cent on BSE,to end the session at Rs 455. During the day,the Bangalore-headquartered firm soared a whopping 15.35 per cent,to hit its life-time high of Rs 464.60.
A similar upmove was witnessed on the National Stock Exchange,where the scrip ended the day 12.11 per cent higher,at Rs 451.90.
In addition,over 1.91 crore shares of the company changed hands on the bourses.
Biocon and Pfizer have entered into a strategic global agreement for the worldwide commercialisation of Biocon’s bio similar version of insulin and insulin analog products.
Meanwhile,the 30-share benchmark Sensex finished the day at 19,983.13,down 185.76 points from previous close.